Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus HEPARIN SODIUM 1 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
EDOXABAN vs HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa). This prevents the conversion of fibrinogen to fibrin and inhibits clot formation.
60 mg orally once daily
Continuous intravenous infusion: initial bolus 80 units/kg (max 10,000 units) followed by infusion at 18 units/kg/hour (usual adult dose 1,000-2,000 units/hour). For prophylactic use: subcutaneous 5,000 units every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Dose-dependent: 30–60 min after 25 U/kg IV, 60–90 min after 100 U/kg IV, 150 min after 400 U/kg IV. Terminal half-life: ~1.5 h (low dose) to ~5 h (high dose). Context: nonlinear due to saturable clearance mechanisms.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Renal (minimal, saturable) and reticuloendothelial system (heparinase). Unchanged heparin: negligible urinary excretion. Metabolites: desulfated heparin via hepatic and extrahepatic heparinase; inactive fragments cleared renally.
Category C
Category A/B
Anticoagulant
Anticoagulant